US · VALN
Valneva SE
- Sector
- Healthcare · Biotechnology
- Headquarters
- Saint-Herblain 44800
- Website
- valneva.com
Price · as of 2024-12-31
$5.35
Market cap 954.23M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $40.90 | +664.49% |
| Intrinsic Value(DCF) | $3.73 | -30.28% |
| Graham-Dodd Method(GD) | $2.00 | -62.62% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.60 | $0.00 | |||
| 2011 | $2.00 | $0.00 | |||
| 2012 | $0.00 | $90.80 | |||
| 2013 | $1.40 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $1.30 | $0.00 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $1.10 | $0.00 | |||
| 2018 | $4.60 | $1.40 | |||
| 2019 | $3.20 | $0.00 | |||
| 2020 | $0.00 | $6.50 | |||
| 2021 | $33.74 | $77.00 | $4,633.19 | $0.00 | $0.00 |
| 2022 | $11.40 | $107.86 | $691.37 | $0.00 | $0.00 |
| 2023 | $7.22 | $31.02 | $0.49 | $0.00 | $79.90 |
| 2024 | $7.07 | $34.91 | $1.58 | $2.00 | $0.00 |
AI valuation
Our deep-learning model estimates Valneva SE's (VALN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $40.90
- Current price
- $5.35
- AI upside
- +664.49%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.73
-30.28% upside
Graham-Dodd
$2.00
-62.62% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VALN | Valneva SE | $5.35 | 954.23M | +553% | -30% | -63% | — | -34.66 | 2.34 | 2.50 | 14.73 | — | 2.72 | 41.89% | 7.86% | -7.22% | -7.91% | 6.06% | -2.55% | 1.19 | 0.56 | 2.61 | 1.78 | 1.50 | -8836.00% | 1032.00% | -6146.00% | -19.71% | -0.59 | -38.00% | 0.00% | 0.00% | 8.17% | 35.45 | -5.65 | 2.79 | 0.09 |
| ARVN | Arvinas, Inc. | $13.27 | 974.25M | +82% | -40% | -97% | — | -10.76 | 2.00 | 3.31 | -2.55 | — | 2.00 | 98.02% | -43.75% | -30.77% | -16.23% | 32.32% | -8.93% | 0.02 | — | 4.92 | 4.88 | 1.78 | -5379.00% | -30.00% | 559.00% | -31.73% | -1.92 | 77.55% | 0.00% | 0.00% | 15.59% | -1.67 | -0.70 | 0.73 | -0.54 |
| ATXS | Astria Therapeutics, Inc. | $12.58 | 718.13M | — | — | — | — | -3.69 | 1.09 | — | -0.26 | — | 1.09 | 0.00% | — | — | -33.52% | 3380.03% | -31.58% | 0.02 | — | 17.49 | 17.15 | 0.58 | -3058.00% | — | 1908.00% | -23.45% | -4.25 | 2470.44% | 0.00% | 0.00% | 0.00% | -0.22 | -0.30 | — | 6.30 |
| AVBP | ArriVent BioPharma, Inc. … | $22.97 | 948.23M | — | — | — | — | -8.55 | 2.67 | — | -5.83 | -47.58 | 2.67 | 0.00% | — | — | -39.36% | -469.29% | -36.75% | 0.00 | — | 13.14 | 12.70 | 0.92 | 1797.00% | — | 2573.00% | -10.20% | -4.06 | -349.38% | 0.00% | 0.00% | 0.00% | -4.98 | -6.69 | — | 22.46 |
| DAWN | Day One Biopharmaceutical… | $10.60 | 1.09B | +166% | +52,842% | — | — | -9.99 | 2.43 | 6.78 | -5.99 | -509.45 | 2.53 | 89.12% | -80.76% | -67.85% | -22.74% | 1066.44% | -19.68% | 0.01 | — | 8.02 | 7.73 | 1.84 | 196.00% | 2060.00% | 2964.00% | -9.71% | -1.71 | 884.82% | 0.00% | 0.00% | 6.71% | -4.96 | -6.09 | 4.01 | 8.31 |
| DNA | Ginkgo Bioworks Holdings,… | $6.75 | 408.98M | +75% | -49% | — | +1,219% | -1.25 | 0.77 | 2.30 | -1.51 | — | 0.87 | 81.48% | -185.29% | -183.81% | -51.08% | -55.89% | -25.05% | 0.82 | — | 4.92 | 4.65 | -0.98 | -4649.00% | -2506.00% | -5323.00% | -45.71% | -1.78 | -31.77% | 0.00% | 0.00% | 0.00% | -1.22 | -2.16 | 2.27 | -7.68 |
| GERN | Geron Corporation | $1.68 | 1.07B | +294,119% | -54% | — | — | -6.40 | 3.99 | 14.52 | -5.38 | — | 3.99 | 98.37% | -225.64% | -226.73% | -66.09% | 7931.16% | -35.34% | 0.43 | -9.39 | 5.56 | 5.04 | -0.28 | -1562.00% | 3238692.00% | 3009.00% | -19.62% | -2.48 | 10011.32% | 0.00% | 0.00% | 0.00% | -4.79 | -3.80 | 10.82 | -2.06 |
| IOVA | Iovance Biotherapeutics, … | $3.86 | 1.28B | +666% | -61% | — | — | -3.46 | 1.94 | 5.14 | -3.10 | — | 3.23 | 97.23% | -153.08% | -148.38% | -55.50% | -89.67% | -42.88% | 0.07 | — | 3.20 | 2.74 | 0.32 | -1484.00% | 6060.00% | -764.00% | -24.83% | -2.19 | -75.14% | 0.00% | 0.00% | 4.22% | -2.74 | -3.29 | 4.20 | -1.24 |
| MBX | MBX Biosciences, Inc. Com… | $32.55 | 1.09B | — | — | — | — | -5.33 | 1.28 | — | -1.00 | -6.55 | 1.28 | 0.00% | — | — | -66.95% | 86.67% | -35.11% | 0.00 | — | 24.19 | 23.78 | 0.72 | 8137.00% | — | 7303.00% | -16.82% | -4.95 | 70.61% | 0.00% | 0.00% | 5.75% | -1.00 | -1.23 | — | 17.45 |
| MGTX | MeiraGTx Holdings plc | $7.56 | 608.51M | +360% | -66% | — | — | -3.01 | 6.57 | 13.39 | -3.51 | -7.13 | 6.65 | 28.51% | -493.44% | -444.10% | -143.48% | -223.66% | -49.55% | 1.25 | -12.37 | 2.03 | 1.88 | 0.15 | 4228.00% | 13742.00% | -1282.00% | -24.57% | -1.72 | -149.07% | 0.00% | 0.00% | 0.00% | -2.60 | -3.90 | 12.82 | -3.93 |
| REPL | Replimune Group, Inc. | $7.65 | 631.68M | — | — | — | — | -3.38 | 2.01 | — | -1.69 | — | 2.01 | 0.00% | — | — | -62.58% | -1380.14% | -47.60% | 0.18 | -33.15 | 7.95 | 7.82 | 0.14 | -525.00% | — | 409.00% | -23.79% | -3.08 | -1049.44% | 0.00% | 0.00% | 4.35% | -1.64 | -2.15 | — | 0.67 |
About Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
- CEO
- Thomas Lingelbach
- Employees
- 713
- Beta
- 1.20
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.73 ÷ $5.35) − 1 = -30.28% (DCF, example).